没有自我焚烧间隔器的抗体-药物联合体表现出强大的抗瘤活性

Victor T Ojo1, Nicholas A Bianchi1, Michele Z Yi1

  • 1School of Pharmacy and Pharmaceutical Sciences, Binghamton University, PO Box 6000, Binghamton, New York 13902-6000, United States.

PubMed
概括

新的抗体-药物联合体 (ADC) 使用一种新的豆类可切割连接器来释放强效的拓酶-I抑制剂 (TOP1i),而无需间隔器. 这些TOP1iADC在胰腺癌模型中显示出强烈的疗效.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K